JP2009541204A5 - - Google Patents

Download PDF

Info

Publication number
JP2009541204A5
JP2009541204A5 JP2008558572A JP2008558572A JP2009541204A5 JP 2009541204 A5 JP2009541204 A5 JP 2009541204A5 JP 2008558572 A JP2008558572 A JP 2008558572A JP 2008558572 A JP2008558572 A JP 2008558572A JP 2009541204 A5 JP2009541204 A5 JP 2009541204A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
chain
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008558572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541204A (ja
JP5028635B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2006/317155 external-priority patent/WO2007148417A1/en
Publication of JP2009541204A publication Critical patent/JP2009541204A/ja
Publication of JP2009541204A5 publication Critical patent/JP2009541204A5/ja
Application granted granted Critical
Publication of JP5028635B2 publication Critical patent/JP5028635B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008558572A 2006-06-21 2006-08-24 Fzd10に対する腫瘍標的化モノクローナル抗体とその使用 Active JP5028635B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81525706P 2006-06-21 2006-06-21
US60/815,257 2006-06-21
PCT/JP2006/317155 WO2007148417A1 (en) 2006-06-21 2006-08-24 Tumor-targeting monoclonal antibodies to fzd10 and uses thereof

Publications (3)

Publication Number Publication Date
JP2009541204A JP2009541204A (ja) 2009-11-26
JP2009541204A5 true JP2009541204A5 (cg-RX-API-DMAC7.html) 2011-07-28
JP5028635B2 JP5028635B2 (ja) 2012-09-19

Family

ID=37616924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008558572A Active JP5028635B2 (ja) 2006-06-21 2006-08-24 Fzd10に対する腫瘍標的化モノクローナル抗体とその使用

Country Status (10)

Country Link
US (2) US8221751B2 (cg-RX-API-DMAC7.html)
EP (2) EP2386577A3 (cg-RX-API-DMAC7.html)
JP (1) JP5028635B2 (cg-RX-API-DMAC7.html)
KR (1) KR101351208B1 (cg-RX-API-DMAC7.html)
CN (1) CN101573383B (cg-RX-API-DMAC7.html)
BR (1) BRPI0621800B8 (cg-RX-API-DMAC7.html)
CA (1) CA2655289C (cg-RX-API-DMAC7.html)
ES (1) ES2405618T3 (cg-RX-API-DMAC7.html)
RU (1) RU2412203C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007148417A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2547421T3 (es) 2005-10-31 2015-10-06 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para diagnosticar y tratar el cáncer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
KR20090080082A (ko) * 2006-11-14 2009-07-23 노파르티스 아게 암을 치료, 진단 또는 검출하는 방법
AU2008333985B2 (en) 2007-11-30 2015-02-05 Kalobios Pharmaceuticals, Inc. Antibodies to the PcrV antigen of pseudomonas aeruginosa
KR101711672B1 (ko) 2008-09-26 2017-03-03 온코메드 파마슈티칼스, 인크. 프리즐드 결합 작용제 및 그의 용도
JP5407042B2 (ja) * 2009-12-16 2014-02-05 公益財団法人ヒューマンサイエンス振興財団 セセルニン−1の使用、滑膜肉腫の予後予測方法及び検査用試薬キット
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
AU2012271413B2 (en) 2011-06-17 2017-07-13 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
JP5944994B2 (ja) * 2011-08-12 2016-07-05 オメロス コーポレーション 抗fzd10モノクローナル抗体およびそれらの使用方法
USRE49477E1 (en) 2012-04-20 2023-03-28 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
WO2014121196A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
JP6796059B2 (ja) 2014-09-12 2020-12-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Wntシグナリングアゴニスト分子
US10100129B2 (en) 2014-11-21 2018-10-16 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
EA038349B1 (ru) 2014-11-21 2021-08-12 Бристол-Маерс Сквибб Компани Антитела, содержащие модифицированные константные участки тяжелой цепи
WO2017026532A1 (ja) * 2015-08-10 2017-02-16 国立大学法人富山大学 抗原特異的モノクローナル抗体作製方法
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
CN113082201B (zh) * 2016-04-01 2024-07-05 上海斯丹赛生物技术有限公司 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
TWI762516B (zh) * 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對fzd10之單株抗體及其用途
JP7617603B2 (ja) 2017-01-11 2025-01-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー R-スポンジン(rspo)サロゲート分子
CA3050133A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
JP7317016B2 (ja) 2017-12-19 2023-07-28 スロゼン オペレーティング, インコーポレイテッド 抗lrp5/6抗体及び使用方法
AU2018393073B2 (en) 2017-12-19 2025-09-18 Surrozen Operating, Inc. Wnt surrogate molecules and uses thereof
US12006368B2 (en) 2017-12-19 2024-06-11 Surrozen Operating, Inc. Anti-frizzled antibodies and methods of use
EP3820906B1 (en) 2018-07-05 2025-10-15 Surrozen Operating, Inc. Multi-specific wnt surrogate molecules and uses thereof
WO2020014271A1 (en) 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング, インコーポレイテッド 肝臓特異的Wntシグナル増強分子およびその使用
CN115724977B (zh) * 2022-11-04 2025-06-13 中国科学技术大学 针对人卷曲受体的单克隆抗体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
ATE181575T1 (de) 1991-04-25 1999-07-15 Chugai Pharmaceutical Co Ltd Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
GB9414580D0 (en) 1994-07-19 1994-09-07 Cancer Res Campaign Tech Materials and methods relating to the diagnosis of synovial sarcomas
US5994098A (en) 1997-06-02 1999-11-30 Smithkline Beecham Corporation Human 7-TM receptor similar to murine frizzled-6 gene
EP0943684A3 (en) 1998-03-10 2002-01-23 Smithkline Beecham Plc Frizzled-like polypeptides and polynucleotides
GB9819681D0 (en) 1998-09-09 1998-11-04 Smithkline Beecham Plc Novel compounds
EP1272224A4 (en) 2000-03-31 2004-09-29 Gene Logic Inc GENE EXPRESSION PROFILES IN ESOPHAGIC TISSUE
AU2001284160A1 (en) 2000-08-19 2002-03-04 Axordia Limited Modulation of stem cell differentiation
US6964849B2 (en) * 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
JP2005508133A (ja) 2001-01-11 2005-03-31 キュラジェン コーポレイション タンパク質およびそれをコードする核酸
AU2002309583A1 (en) 2001-04-18 2002-11-05 Protein Desing Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US20030044409A1 (en) * 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
WO2002088081A2 (en) 2001-05-01 2002-11-07 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
WO2003004045A2 (en) 2001-07-05 2003-01-16 Xenon Genetics, Inc. Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
WO2004020668A2 (en) * 2002-08-30 2004-03-11 Oncotherapy Science, Inc. Method for treating synovial sarcoma
CA2501235A1 (en) 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
ES2381841T3 (es) * 2003-07-11 2012-06-01 Oncotherapy Science, Inc. Método para tratar el sarcoma sinovial
EP1789549A1 (en) 2004-08-05 2007-05-30 The University of Tokyo Method for treating synovial sarcoma using sirna for fzd10

Similar Documents

Publication Publication Date Title
JP2009541204A5 (cg-RX-API-DMAC7.html)
RU2009101788A (ru) Направленные на опухоль моноклональные антитела против fzd10 и их применение
RU2011103199A (ru) Антитела против cdh3, меченные радиоизотопной меткой, и их применение
US8426562B2 (en) Methods and compositions for modulating tumor cell activity
JP2008538289A5 (cg-RX-API-DMAC7.html)
JP2005528099A5 (cg-RX-API-DMAC7.html)
JP5941615B2 (ja) ヒトcxcl1タンパク質の免疫学的測定方法
JP6342812B2 (ja) 鉄関連障害を診断および治療するための組成物および方法
JP6586648B2 (ja) 抗プログルカゴン抗体
JP2020526478A5 (cg-RX-API-DMAC7.html)
JP2020534830A5 (cg-RX-API-DMAC7.html)
JP2010523096A5 (cg-RX-API-DMAC7.html)
JP2019513018A5 (cg-RX-API-DMAC7.html)
JP2012012402A5 (cg-RX-API-DMAC7.html)
RU2009120052A (ru) Композиции и способы связывания сфингозин-1-фосфата
JP2005515963A5 (cg-RX-API-DMAC7.html)
JP2005528914A5 (cg-RX-API-DMAC7.html)
JP6081699B2 (ja) Il−28bの分析方法
JP2010505426A (ja) 非機能性p2x7受容体に対する抗体を産生するハイブリドーマ
JP2018518151A5 (cg-RX-API-DMAC7.html)
JP2010501164A5 (cg-RX-API-DMAC7.html)
JP2017538439A5 (cg-RX-API-DMAC7.html)
JP2007526891A5 (cg-RX-API-DMAC7.html)
CN114174341A (zh) 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法
JP2018520127A5 (cg-RX-API-DMAC7.html)